Ligands used for tumor targeting include antibodies (trastuzumab for HER2-positive breast cancer), peptides (RGD peptides for integrin αvβ3), aptamers (AS1411 targeting nucleolin), and small molecules (folic acid for folate receptors) [100]. Here, ERBB2 is linked to neoplasm.